Results 201 to 210 of about 128,389 (322)

[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling. [PDF]

Oncol Rep
Liu YH, Zhu M, Lei PP, Pan XY, Ma WN.
europepmc   +1 more source

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification. [PDF]

Exp Hematol Oncol, 2022
Zeng D, Gao M, Zheng R, Qin R, He W, Liu S, Wei W, Huang Z.   +7 more
europepmc   +1 more source

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia

Autophagy, 2015
Xian Zeng, Hui Zhao, Yubin Li, Jiajun Fan, Yun Sun, Shao-Kai Wang, Ziyu Wang, P. Song, D. Ju   +8 more
semanticscholar   +1 more source

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy. [PDF]

Front Immunol
Hsu MT, Willimsky G, Hansmann L, Blankenstein T.   +3 more
europepmc   +1 more source

BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP. [PDF]

Cell Death Dis, 2023
Feng L, Ding R, Qu X, Li Y, Shen T, Wang L, Li R, Zhang J, Ru Y, Bu X, Wang Y, Li M, Song W, Shen L, Zhang P.   +14 more
europepmc   +1 more source

Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck [PDF]

, 2000
Jack M. Lionberger, Matthew B. Wilson, Thomas E. Smithgall   +2 more
openalex   +1 more source

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

Cancer Cell, 2009
T. O'hare, W. Shakespeare, Xiaotian Zhu, C. Eide, V. Rivera, Frank Y. Wang, Lauren T. Adrian, Tianjun Zhou, Wei-sheng Huang, Qihong Xu, C. Metcalf, J. Tyner, M. Loriaux, A. Corbin, Scott D. Wardwell, Y. Ning, J. Keats, Yihan Wang, R. Sundaramoorthi, Mathew P. Thomas, Dong Zhou, Joseph T Snodgrass, L. Commodore, T. Sawyer, D. Dalgarno, M. Deininger, B. Druker, T. Clackson   +27 more
semanticscholar   +1 more source

CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. [PDF]

Cell Death Discov
Khamidullina AI, Yastrebova MA, Bruter AV, Nuzhina JV, Vorobyeva NE, Khrustaleva AM, Varlamova EA, Tyakht AV, Abramenko IE, Ivanova ES, Zamkova MA, Li J, Lim CU, Chen M, Broude EV, Roninson IB, Shtil AA, Tatarskiy VV.   +17 more
europepmc   +1 more source

Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin. [PDF]

Cell Cycle, 2023
Yin SS, Chen C, Liu Z, Liu SL, Guo JH, Zhang C, Zhang QW, Gao FH.   +7 more
europepmc   +1 more source

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [PDF]

Cancer Res
Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, Sun R, Jia Y, Wang Y, Shen J, Wang D, Wang S, Jiang H, Jiang B, Yang X, Xie C.   +15 more
europepmc   +1 more source